Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-04-16 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Clarification/ confirmation on the news item appearing in www.cnbctv18.com
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) providing clarification and confirmation regarding a news item about a US court order related to a patent case. It references previous disclosures and states the company is in the process of assessing the impact and will update the exchanges accordingly. The document is short (3669 characters), does not contain financial statements or detailed financial data, and is primarily a regulatory communication responding to market surveillance queries. It does not present financial results, management discussion, or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance communications that do not fit other categories.
2025-04-16 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the applicability of a SEBI circular on fund raising by issuance of debt securities by large corporates. It states that the company does not qualify as a 'Large Corporate' under the specified SEBI framework. The document is short (1546 characters), contains no financial data or report, and is essentially a regulatory compliance statement or clarification. It is not a financial report, earnings release, or capital update per se, but a regulatory filing related to compliance with SEBI rules. Therefore, it fits best under Regulatory Filings (RNS).
2025-04-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025. It is a confirmation certificate from the Registrar and Share Transfer Agent regarding dematerialisation of securities and related compliance. The document is short (3571 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents and certifications that do not fit other specific categories.
2025-04-07 English
Certificate under Reg. 74(5) of SEBI (Depositories and Participant) Regulations, 2018 for the quarter ended on March 31, 2025.
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025. It is a confirmation certificate from the Registrar and Share Transfer Agent regarding dematerialisation of securities and related compliance. The document is short (3571 characters) and primarily serves as a compliance certificate rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. It is an attestation/certification document submitted to stock exchanges as per regulatory requirements. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance certificate and not a full report or announcement of a report.
2025-04-07 English
Lupin Healthcare (UK) Limited, a wholly owned subsidiary of the Company, has acquired the entire share capital of Renascience Pharma Limited, United Kingdom.
M&A Activity Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing that Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, has acquired the entire share capital of Renascience Pharma Limited in the UK. It includes detailed disclosures as required by SEBI circulars, financial details of the acquired company, and a press release about the acquisition. The document is an announcement of a merger/acquisition transaction, not a full merger proxy statement or tender offer filing. It is not a full annual or interim report, earnings release, or other financial report. The content fits the category of M&A Activity announcements, which cover merger proposals or takeover bids and related disclosures. Therefore, the appropriate classification is M&A Activity (Code: TAR). The document length and detail support a high confidence level.
2025-04-02 English
Acquisition
M&A Activity Classification · 95% confidence The document is a formal announcement addressed to stock exchanges (NSE and BSE) regarding Lupin Healthcare (UK) Limited's acquisition of Renascience Pharma Limited. It includes detailed disclosures as per SEBI regulations about the acquisition, such as the target entity's financials, percentage acquired, consideration, and background. Additionally, it contains a press release describing the acquisition and its strategic rationale. There are no financial statements or detailed financial performance data typical of annual or interim reports. The document is clearly an announcement of a merger/acquisition transaction, not a full merger filing or proxy statement. Therefore, the most appropriate classification is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2025-04-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.